Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
Publication|Articles|December 23, 2024
Peers & Perspectives in Oncology
- December I, 2024
- Pages: 72
Roundtable Roundup: Choosing a Bispecific Antibody for R/R Multiple Myeloma
Author(s)Targeted Oncology Staff
Fact checked by: Dylann Bailey
In separate, live events, Binod Dhakal, MD, MS; and Laahn H. Foster, MD, polled oncologists on therapeutic options for a patient with multiple myeloma and progressive disease.
Advertisement
CASE SUMMARY
- A 72-year-old man was diagnosed 6 years ago with multiple myeloma, with 60% plasma cells and translocation 14;20.
- Medical history: respiratory infections (2 episodes of pneumonia and multiple episodes of bronchitis over prior 10 years)
- He received 5 prior lines of therapy, most recently chimeric antigen receptor T-cell infusion
- He now presents with progressive disease (elevated free light chain, creatinine level of 2.3 mg/dL)
- ECOG performance status: 2
CASE UPDATE
Talquetamab is initiated via step-up dosing (SUD) up to 800 μg/kg every 2 weeks (Q2W).
Articles in this issue
almost 2 years ago
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCCalmost 2 years ago
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLLalmost 2 years ago
Multidisciplinary GVHD Care Reveals Unmet Needs and OpportunitiesAdvertisement
Related to this article
Etentamig, a BCMAxCD3 bispecific antibody, was submitted for potential FDA approval based on the phase 3 CERVINO trial in relapsed/refractory multiple myeloma.
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5